Search results for "slip"

showing 10 items of 471 documents

Dietary strategy for prevention and management of dyslipidemia: international guidelines

2012

Primary prevention of cardiovascular disease should begin with a detailed metabolic study of our patients who must follow a nutritional therapy. Recently, new guidelines ESC/EAS 2011 on the treatment of dyslipidemia have been drawn up, according to which it is possible to arrive at desirable values of cholesterol and triglycerides with a synergy between drug treatment and adequate diet therapy. At this time, Mediterranean diet has been undergoing a radical transformation: there is hyperalimentation of the Mediterranean diet in all its components. The effectiveness of the Mediterranean diet on the reduction of lipids has been demonstrated, and the problem is how to implement this diet in the…

medicine.medical_specialtyeducation.field_of_studySettore MED/09 - Medicina InternaNutrition and DieteticsMediterranean dietCholesterolDiet therapybusiness.industryEndocrinology Diabetes and MetabolismPopulationDiseasemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolarechemistry.chemical_compoundchemistryDiabetes mellitusmedicinePhysical therapyMedical nutrition therapyIntensive care medicineeducationbusinessDyslipidemiaDietDyslipidemia Prevention Guidelines EducationFood ScienceMediterranean Journal of Nutrition and Metabolism
researchProduct

Control de la dislipemia en grupos clínicos especiales: mujeres, ancianos, VIH, enfermedad renal crónica, pacientes con síndrome metabólico

2011

There is still some disagreement about how dyslipidemia should be treated in particular population groups. This article provides a review of indications for lipid-lowering treatment, preferably for primary prevention, in specific groups of patients: women, the elderly, and those with an HIV infection, chronic kidney disease or metabolic syndrome. Special emphasis is placed on data obtained in the JUPITER trial and in other studies of rosuvastatin.

medicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationHuman immunodeficiency virus (HIV)medicine.disease_causemedicine.diseaseInternal medicineJUPITER trialPrimary preventionmedicineRosuvastatinMetabolic syndromeCardiology and Cardiovascular MedicinebusinesseducationDyslipidemiamedicine.drugKidney diseaseRevista Española de Cardiología Suplementos
researchProduct

Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters.

2005

In hyperandrogenic women, several phenotypes may be observed. This includes women with classic polycystic ovary syndrome (C-PCOS), those with ovulatory (OV) PCOS, and women with idiopathic hyperandrogenism (IHA), which occurs in women with normal ovaries. Where other causes have been excluded, we categorized 290 hyperandrogenic women who were seen consecutively for this complaint between 1993 and 2004 into these three subgroups. The aim was to compare the prevalence of obesity, insulin resistance, and dyslipidemia as well as increases in C-reactive protein and homocysteine in these different phenotypes with age-matched ovulatory controls of normal weight (n = 85) and others matched for body…

medicine.medical_specialtyendocrine system diseasesHomocysteineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryBiochemistryBody Mass IndexNORMAL MENSESchemistry.chemical_compoundEndocrinologyInsulin resistanceRisk FactorsInternal medicineparasitic diseasesmedicineHumansInsulinANDROGEN EXCESSDEHYDROEPIANDROSTERONE SULFATEPLASMAbusiness.industryInsulinBiochemistry (medical)Hyperandrogenismnutritional and metabolic diseasesCholesterol LDLPOLYCYSTIC-OVARY-SYNDROMELuteinizing Hormonemedicine.diseaseObesityPolycystic ovaryfemale genital diseases and pregnancy complicationsEndocrinologyC-Reactive ProteinPhenotypechemistryCardiovascular DiseasesFemaleSENSITIVITYInsulin ResistancebusinessBody mass indexDyslipidemiaPolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.

2019

In general, both European and American clinical guidelines have addressed the management of atherogenic dyslipidaemia in an unconvincing and even superficial way, largely because of the available therapeutic limitations. Consequently, this type of dyslipidaemia is underdiagnosed, under-treated, and under-controlled. Given the recent presentation of the 2019 guidelines of the European Atherosclerosis Society and the European Society of Cardiology on the management of dyslipidaemias, it seems appropriate to examine its position with respect to atherogenic dyslipidaemia and/or its main components, the increase in triglyceride-rich lipoproteins, and the decrease of high-density lipoprotein chol…

medicine.medical_specialtyendocrine system diseaseschemistry.chemical_compoundTriglycerides/HDL CholesterolInternal medicineMedicineHumanscardiovascular diseasesTriglyceridesGeneral Environmental ScienceLipoprotein cholesterolDyslipidemiasbusiness.industryCholesterolCholesterol HDLGeneral Engineeringnutritional and metabolic diseasesAtherosclerosisEuropechemistryPractice Guidelines as TopicCardiologyEuropean atherosclerosis societyGeneral Earth and Planetary Scienceslipids (amino acids peptides and proteins)businessClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Association of Aldosterone and Cortisol with Cardiovascular Risk Factors in Prehypertension Stage

2012

Background. The Pakistani population has higher incidence of cardiovascular (CV) diseases at younger ages, due to undiagnosed, uncontrolled hypertension (HTN). A variety of associated HTN stressors is also reported. The study plans to understand the variables associated with initiation of HTN in this population.Objective. To find plasma aldosterone and cortisol relationship with some CV risk factors (obesity, dyslipidemia, hyperglycemia, sodium and potassium) in different stages of HTN particularly prehypertension.Subjects and Methods. The study conducted on 276 subjects (25–60 years), classified into prehypertensive (n=55), HTN stage-1 (n=70) and II (n=76) according to 7th JNC report and c…

medicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemWaistArticle SubjectPopulationOverweightPrehypertensionchemistry.chemical_compoundInternal medicineInternal Medicinemedicinecardiovascular diseaseseducationeducation.field_of_studyAldosteronebusiness.industrymedicine.diseaseObesityEndocrinologychemistrylcsh:RC666-701medicine.symptombusinessBody mass indexDyslipidemiaResearch ArticleInternational Journal of Hypertension
researchProduct

0102: Atherogenic lipid profile and lipid peroxide products of patients with rheumatoid arthritis

2016

IntroductionRheumatoid Arthritis (RA) is a chronic relapsing immune-inflammatory multisystem disease with predominant synovial proliferation and destruction of articular cartilage. Patients with RA have a higher riskof mortality related to increased risk of cardiovascular disease with atherogenic lipid profile. In recent years, oxidative stress in RA patients has received considerable attention and has been implicated as mediators of tissue damage and cardio-vascular disease in patients with RA.The aim of the present study was to assess the lipid profile and lipid peroxide products of patients with rheumatoid arthritis compared with healthy controls.Patients and MethodsThe study included 70…

medicine.medical_specialtymedicine.diagnostic_testLipid peroxideCholesterolbusiness.industryLipid metabolismmedicine.diseaseRheumatologychemistry.chemical_compoundEndocrinologychemistryDiabetes mellitusRheumatoid arthritisInternal medicinemedicineCardiology and Cardiovascular MedicineLipid profilebusinessDyslipidemiaArchives of Cardiovascular Diseases Supplements
researchProduct

The role of fibrate treatment in dyslipidemia: an overview.

2012

Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias. Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributin…

medicine.medical_specialtymedicine.drug_classPeroxisome proliferator-activated receptorAdipokineFibratechemistry.chemical_compoundInternal medicineDrug DiscoverymedicineAnimalsHumansTriglyceridesDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationTriglycerideCholesterolbusiness.industryFibric Acidsnutritional and metabolic diseasesLipid metabolismCholesterol LDLmedicine.diseaseFibrates dyslipidemia cardiovascular risk diabetes.EndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent pharmaceutical design
researchProduct

Chronic kidney disease and dyslipidaemia

2016

Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and …

medicine.medical_specialtymedicine.medical_treatmentRenal functionDisease030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumans030212 general & internal medicineRenal replacement therapyRenal Insufficiency ChronicIntensive care medicineDyslipidemiasGeneral Environmental ScienceCardiovascular mortalitybusiness.industryAnticholesteremic AgentsGeneral EngineeringCholesterol LDLmedicine.diseaseRenal Replacement TherapyCardiovascular DiseasesRenal transplantDisease ProgressionPhysical therapyGeneral Earth and Planetary SciencesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessVery high riskDyslipidemiaKidney diseaseClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Dise…

2020

Diabetes mellitus is a heterogeneous and dysmetabolic chronic disease in which the laboratory plays a fundamental role, from diagnosis to monitoring therapy and studying complications. Early diagnosis and good glycemic control should start as early as possible to delay and prevent metabolic and cardio-vascular complications secondary to this disease. Glycated hemoglobin is currently used as the reference parameter. The accuracy of the glycated hemoglobin dosage may be compromised in subjects suffering from chronic renal failure and terminal nephropathy, affected by the reduction in the survival of erythrocytes, with consequent decrease in the time available for glucose to attach to the hemo…

medicine.medical_specialtyobesitykidney diseaseglycated albumin cerebrovascular disease diabetes dyslipidemia obesity kidney disease therapy cardiovascular diseaselcsh:Medicine030209 endocrinology & metabolismDiseaseReview030204 cardiovascular system & hematologyNephropathy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinecardiovascular diseaseInternal medicineDiabetes mellitusMedicineGlycemictherapydiabetesbusiness.industrylcsh:RdyslipidemiaGeneral Medicinecardiovascular disease; cerebrovascular disease; diabetes; dyslipidemia; glycated albumin; kidney disease; obesity; therapymedicine.diseasecerebrovascular diseasechemistryBiomarker (medicine)glycated albuminGlycated hemoglobinbusinessDyslipidemiaKidney diseaseJournal of Clinical Medicine
researchProduct

Anthropometric indices, lipid profile, and lipopolysaccharide-binding protein levels in metabolic endotoxemia: A case-control study in Calabar Metrop…

2020

Objectives: To determine the anthropometric indices, lipopolysaccharide-binding proteins (LBP), and lipid profile in patients with metabolic endotoxemia. Methods: The study comprised of 47 patients with metabolic endotoxemia (the metabolic endotoxemia group) and 43 controls (the control group). Patients in the metabolic endotoxemia group were categorized further into three subgroups including the normal weight group (n=8), the overweight group (n=12) and the obese group (n=27). Height, weight, waist, and hip circumference were measured, and waist-hip ratio (WHR) and body mass index (BMI) were calculated. LBP was determined by ELISA and total cholesterol, triglycerides, high density lipoprot…

metabolic endotoxemia; gut; microbiota; lipopolysaccharide-binding protein; body mass index; lipid profile; anthropometric indicesmedicine.medical_specialtyVery low-density lipoproteinWaistmedicine.diagnostic_testbusiness.industrylcsh:Medical emergencies. Critical care. Intensive care. First aidlcsh:RC86-88.9General MedicineOverweightmedicine.diseasechemistry.chemical_compoundEndocrinologyHigh-density lipoproteinchemistryInternal medicineLow-density lipoproteinmedicinelipids (amino acids peptides and proteins)medicine.symptomLipid profilebusinessBody mass indexDyslipidemiaJournal of Acute Disease
researchProduct